Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
226
Views
1
CrossRef citations to date
0
Altmetric
Commentaries

Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia

Stefano Molicaa Department Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UKCorrespondence[email protected]
,
David John Allsupa Department Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK;b Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK
&
Aaron Polliackc Department of Hematology, Hadassah-Hebrew-University Medical Center, Jerusalem, Israel
Pages 1771-1773 | Received 29 May 2022, Accepted 30 May 2022, Published online: 15 Jun 2022

References

  • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.
  • Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
  • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
  • Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
  • Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial lancet oncol. 2019;20(1):e10]. Lancet Oncol. 2019;20(1):43–56.
  • Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
  • Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020(1):336–345.
  • Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799–1807.
  • Maddocks J, Ruppert KJ, Lozanski AS, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87.
  • Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615.
  • UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–1572.
  • Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020;13(1):66–76.
  • Collins J, Stump SE, Heiling H, et al. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2022;Mar 6;1-8.
  • Sattler ELP, Lee JS, Perri M III, et al. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30(6):383–399.
  • Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249–2259.
  • Tedeschi A, Frustaci AM, Mauro FR, et al. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? Blood Adv. 2021;5(24):5490–5500.
  • Ross XS, Gunn KM, Suppiah V, et al. A review of factors influencing non-adherence to oral antineoplastic drugs. Support Care Cancer. 2020;28(9):4043–4050.
  • Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452.
  • Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of phase III randomized study of Zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL/SLL. Eur Hematol Assoc. 2021;:LB 1900.
  • Molica S, Bombaci F, Cuneo A, et al. Living with CLL: a quantitative cross-sectional study of Italian patients on behalf of AIL (associazione italiana contro le Leucemie-Linfomi e mielomi). Eur Hematol Assoc. 2020;:EP1743.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.